Castle Biosciences' TissueCypher Test Hits 100,000 Orders, Expanding Precision Risk Assessment for Barrett's Esophagus — Castle Biosciences, Inc.

Event summary

Castle Biosciences' TissueCypher® Barrett's Esophagus Test surpassed 100,000 clinical test orders as of June 16, 2026.
The AI-derived precision medicine test predicts a patient's five-year risk of progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma.
TissueCypher is backed by over 17 peer-reviewed publications and studied in biopsies from more than 8,000 patients.
The test uses an AI-derived spatialomics approach to identify molecular signatures that precede the development of dysplasia.
Castle Biosciences aims to tailor management decisions based on individual patient risk profiles.

The big picture

Castle Biosciences' achievement of 100,000 test orders for TissueCypher underscores the growing demand for precision medicine in managing Barrett's esophagus, a precursor to esophageal adenocarcinoma. The test's AI-derived spatialomics approach positions it as a key player in the shift towards personalized healthcare, potentially reducing uncertainty for patients and optimizing clinical decision-making. This milestone highlights the strategic importance of integrating advanced molecular diagnostics into standard medical practices, particularly in fields with high unmet needs for risk stratification.

What we're watching

Adoption Pace: How quickly TissueCypher will be integrated into routine endoscopic practices and its impact on patient management.
Clinical Validation: Whether subsequent studies will continue to support the test's ability to predict progression risk accurately.
Market Expansion: The pace at which Castle Biosciences can expand the use of TissueCypher beyond Barrett's esophagus to other gastrointestinal conditions.